Home Cart Sign in  
Chemical Structure| 603139-19-1 Chemical Structure| 603139-19-1

Structure of Odanacatib
CAS No.: 603139-19-1

Chemical Structure| 603139-19-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Odanacatib is a potent, selective, and neutral inhibitor of cathepsin K (human/rabbit) with IC50 of 0.2 nM/1 nM, and demonstrated high selectivity versus off-target cathepsin B, L, S.

Synonyms: MK-0822

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Odanacatib

CAS No. :603139-19-1
Formula : C25H27F4N3O3S
M.W : 525.56
SMILES Code : CC(C)(F)C[C@H](N[C@@H](C1=CC=C(C2=CC=C(S(=O)(C)=O)C=C2)C=C1)C(F)(F)F)C(NC3(C#N)CC3)=O
Synonyms :
MK-0822
MDL No. :MFCD11042419
InChI Key :FWIVDMJALNEADT-SFTDATJTSA-N
Pubchem ID :10152654

Safety of Odanacatib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Odanacatib

pyroptosis

Isoform Comparison

Biological Activity

Target
  • Cysteine Protease

    Cathepsin K (rabbit), IC50:1 nM

    Cathepsin K (human), IC50:0.2 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
female hookworms 1 μM 10 minutes Measure the inhibition of hookworm cysteine protease activity, showing 49.8% residual activity after ODN treatment. PMC5039492
male hookworms 1 μM 10 minutes Measure the inhibition of hookworm cysteine protease activity, showing 40.2% residual activity after ODN treatment. PMC5039492
Caki-1 cells 2 μM 24 hours To investigate the effect of Odanacatib on Raptor protein stability, results showed that Odanacatib induces dephosphorylation of OTUB1 and Src, leading to downregulation of Raptor protein. PMC10276854
A549 cells 2 μM 24 hours To investigate the effect of Odanacatib on Raptor protein stability, results showed that Odanacatib induces dephosphorylation of OTUB1 and Src, leading to downregulation of Raptor protein. PMC10276854
DU145 cells 2 μM 24 hours To investigate the effect of Odanacatib on Raptor protein stability, results showed that Odanacatib induces dephosphorylation of OTUB1 and Src, leading to downregulation of Raptor protein. PMC10276854

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice colon cancer xenograft model Oral 3.606 mg/kg/week once a week until the end of sample harvest Odanacatib reversed the CTSK promoted subcutaneous tumor growth and pulmonary metastatic foci formation PMC6889446
Golden Syrian hamsters Ancylostoma ceylanicum infection model Oral 100 mg/kg single dose Evaluate the efficacy of ODN against hookworm infection, showing a 73% reduction in hookworm burden and a 51% reduction in the parasite’s cysteine protease activity. PMC5039492
BALB/cJ mice Periodontitis mouse model Oral 3.606 mg /kg/wk or 0.7212 mg/kg/wk Once a week, until the end of sample harvest Odanacatib reduced the number of osteoclasts, macrophages, and T cells, as well as the expression of Toll-like receptors (TLRs) in the periodontitis lesion area, demonstrating its bone-protective and anti-inflammatory effects on periodontitis. PMC4648620
BALB/c-Nude mice Xenograft model Intraperitoneal injection 5 mg/kg Once daily for 20 days To investigate the effect of Odanacatib on Raptor protein expression in vivo, results showed that Odanacatib alone or in combination with oxaliplatin induced downregulation of Raptor protein. PMC10276854

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00242476 Vitamin D Deficiency Phase 2 Completed - -
NCT00397683 Osteoarthritis Phase 2 Terminated - United States, California ... More >> Call for Information Palm Desert, California, United States, 92260 Call for Information Pomona, California, United States, 91767 Call for Information Torrance, California, United States, 90505 Call for Information Upland, California, United States, 91786 United States, Florida Call for Information Coral Gables, Florida, United States, 33134 Call for Information Hialeah, Florida, United States, 33010 Call for Information South Miami, Florida, United States, 33143-0000 United States, New York Call for Information Rochester, New York, United States, 14168 Call for Information Rochester, New York, United States, 14609 Call for Information Rochester, New York, United States, 14618 United States, Pennsylvania Call for Information Norristown, Pennsylvania, United States, 19401 Call for Information Perkasie, Pennsylvania, United States, 18944 Chile Merck Sharp & Dohme (I.A.) Corp. Santiago, Chile, 6761641 Colombia Frosst Laboratories Inc. Bogota, Cundinamarca, Colombia Mexico Merck Sharp & Dohme De Mexico, S.A. De C.V. Mexico, D.f., Mexico, 1090 Poland MSD Polska Sp. z o.o. Dzial Medyczny Warszawa, Poland, 00-867 Less <<
NCT00112437 Osteoporosis Phase 2 Completed - -
NCT00863590 Osteoporosis Phase 1 Completed - -
NCT00885170 Osteoporosis Phase 2 Completed - -
NCT00770159 Osteoporosis Phase 1 Completed - -
NCT00885170 - Completed - -
NCT00399802 Breast Cancer ... More >> Metastatic Bone Disease Less << Phase 2 Completed - -
NCT00399802 - Completed - -
NCT00112437 - Completed - -
NCT01552122 Osteoporosis ... More >>Postmenopausal Osteoporosis Less << Phase 3 Withdrawn February 2015 -
NCT00620113 Osteoporosis Postmenopausal Phase 2 Completed - -
NCT00729183 Osteoporosis Phase 3 Completed - -
NCT00729183 - Completed - -
NCT00692458 Breast Cancer Phase 3 Withdrawn(Withdrawn for admini... More >>strative reasons) Less << September 2008 -
NCT01120600 Osteoporosis Phase 3 Completed - -
NCT00529373 Postmenopausal Osteoporosis Phase 3 Completed - -
NCT00863525 Osteoporosis Phase 1 Completed - -
NCT00691899 Prostate Cancer Phase 3 Withdrawn(Withdrawn for admini... More >>strative reasons) Less << September 2008 -
NCT00769418 Osteoporosis Phase 1 Completed - -
NCT01630616 - Terminated - -
NCT00620113 - Completed - -
NCT01068262 Osteoporosis Phase 1 Completed - -
NCT01630616 Osteoporosis Phase 1 Terminated - -
NCT01512693 Hepatic Insufficiency PHASE1 COMPLETED 2012-04-24 -
NCT01512693 Hepatic Insufficiency PHASE1 COMPLETED 2012-04-24 -
NCT01068262 - Completed - -
NCT01803607 - Terminated(Study halted premat... More >>urely due to low enrollment.) Less << - -
NCT01512667 Renal Insufficiency PHASE1 COMPLETED 2012-08-22 -
NCT01512667 Renal Insufficiency PHASE1 COMPLETED 2012-08-22 -
NCT01803607 Osteoporosis Phase 3 Terminated(Study halted premat... More >>urely due to low enrollment.) Less << - -
NCT01120600 - Completed - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.90mL

0.38mL

0.19mL

9.51mL

1.90mL

0.95mL

19.03mL

3.81mL

1.90mL

References

 

Historical Records

Categories